Sangamo Therapeutics Inc (NASDAQ:SGMO) price closed higher on Monday, November 20, jumping 7.88% above its previous close.
A look at the daily price movement shows that the last close reads $0.38, with intraday deals fluctuated between $0.382 and $0.451. The company’s 5Y monthly beta was ticking 1.12. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.76 and 52-week low of $0.29. The stock subtracted -19.48% on its value in the past month.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Sangamo Therapeutics Inc, which has a market valuation of $73.60 million, is expected to release its quarterly earnings report Feb 20, 2024 – Feb 26, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give SGMO a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 10 analysts have assigned SGMO a recommendation rating as follows: 4 rate it as a Hold; 4 advise Buy while 1 analyst(s) assign an Overweight rating. 1 analyst(s) have tagged the Sangamo Therapeutics Inc (SGMO) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that SGMO’s price is at present -4.23% off the SMA20 and -28.74% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 45.03, with weekly volatility standing at 16.14%. The indicator jumps to 14.49% when calculated based on the past 30 days. Sangamo Therapeutics Inc (NASDAQ:SGMO)’s beta value is holding at 0.95, while the average true range (ATR) indicator is currently reading 0.06.
Turning out attention to how the Sangamo Therapeutics Inc stock has performed in comparison to its peers in the industry, here’s what we find: SGMO’s stock is 7.88% on the day and -88.66% in the past 12 months, while Biogen Inc. (BIIB) traded 0.93%% in the last session and was positioned -23.71% down on its price 12 months ago. Turning out attention to how the Sangamo Therapeutics Inc stock has performed in comparison to its peers in the industry, here’s what we find: SGMO’s stock is 7.88% on the day and -88.66% in the past 12 months, while Biogen Inc. (BIIB) traded 0.93%% in the last session and was positioned -23.71% down on its price 12 months ago. Another comparison is with Johnson & Johnson (JNJ) whose stock price was up 0.88%% in the last trading session, and has flourished -14.81% over the past year. Also, BioMarin Pharmaceutical Inc. (BMRN) showed up trend of 0.01%% while its price kept floating at -1.11% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.74% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.58%.
An analysis of the Sangamo Therapeutics Inc (NASDAQ:SGMO) stock in terms of its daily trading volume indicates that the 3-month average is 2.06 million. However, this figure increases on the past 10-day timeline to an average of 2.74 million.
Current records show that the company has 166.79M in outstanding shares. The insiders’ percentage holdings are 10.74% of outstanding shares while the percentage share held by institutions stands at 58.06%. The stats also highlight that short interest as of Oct 30, 2023, stood at 11.59 million shares, which puts the short ratio at the time at 4.71. From this we can glean that short interest is 6.53% of company’s current outstanding shares. Notably, we see that shares short in October rose slightly given the previous month’s figure stood at 9.11 million. But the -86.78% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
